Lexicon Pharmaceuticals, Inc. — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014. The company is a clinical-stage biopharmaceutical business focused primarily on developing LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome. Amounts below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $0.676 | $0.214 | $0.953 | $0.574 |
| Operating expenses | $26.787 | $28.838 | $57.536 | $54.753 |
| Operating loss | $(26.111) | $(28.624) | $(56.583) | $(54.179) |
| Net loss | $(26.028) | $(29.080) | $(56.863) | $(55.054) |
| Net loss per share | $(0.05) | $(0.06) | $(0.11) | $(0.11) |
- Six-month operating cash use was $49.974 million, versus $45.403 million in 2013. Investing activities provided $41.791 million, primarily from net investment maturities; financing activities used $1.591 million.
- Cash and cash equivalents were $27.725 million, and short-term investments were $51.319 million, at June 30, 2014. Combined, these totaled about $79.0 million, down from $129.1 million at year-end 2013. Short-term investments included $0.430 million of restricted investments.
- Total debt on the balance sheet was about $21.0 million, including $1.783 million current and $19.255 million long-term. The mortgage principal was $21.0 million, bears fixed interest at 8.23%, and matures in April 2017.
- Total liabilities were $107.396 million; accumulated deficit was $1.061 billion. The filing does not report a conventional gross margin, and revenue was small relative to research and development costs.
Changes versus the prior comparable period
- Q2 revenue increased 216% to $0.676 million; six-month revenue rose 66% to $0.953 million. The increase was mainly collaborative research revenue, including support for LX4211 Phase 2 development in type 1 diabetes and other functional genomics work.
- Q2 R&D expense declined 11% to $21.187 million, while six-month R&D expense increased 3% to $45.140 million. The six-month increase reflected higher external clinical and preclinical costs and severance, partly offset by lower personnel and facility-related costs.
- G&A expense increased 10% in Q2 to $5.152 million and 20% for six months to $10.806 million, driven principally by severance and higher commercialization-preparation consulting costs.
- Q2 net loss narrowed, but six-month net loss increased. The company recorded a $1.590 million six-month noncash increase in the fair value of the Symphony Icon purchase liability, compared with $1.741 million in 2013.
Outlook, risks, and notable items
- Management said existing unrestricted cash and investments, together with expected collaboration, license, and other receipts, should fund operations for at least the next 12 months. This is management’s estimate, not a guarantee; the company expects substantial capital needs and may need additional financing afterward.
- In January 2014, Lexicon committed to reduce its workforce by about 125 employees, approximately 50% of staff, and concentrate resources on its late-stage programs. Most reductions were completed by the end of Q2. Expected cash restructuring charges were $5.7–$6.0 million; $5.4 million had been incurred by June 30, with $1.6 million of future payments accrued.
- Lexicon has a history of losses and relies heavily on collaborations, licenses, milestones, and potential royalties. Revenue from a limited number of sources is uncertain and dependent on development progress and collaborator decisions. Drug development, regulatory approval, commercialization, reimbursement, manufacturing, and financing are significant risks.
- The Symphony Icon arrangement may require up to $45 million of additional contingent payments tied to specified licensing receipts or U.S. regulatory approval for relevant products. The related purchase consideration liability was valued at $29.3 million at June 30; its valuation uses significant unobservable assumptions.
- A Texas Enterprise Fund award carries job-creation obligations. The filing describes potential repayment exposure of up to approximately $14.2 million if no qualifying jobs are created, before credits; it identifies approximately $1.5 million of potential exposure through 2014, also before credits.
- The company reported ordinary-course legal claims that it did not expect, individually or collectively, to have a material adverse effect. It also disclosed a maximum potential future payment of $4.3 million under its New Jersey lease guarantee.
Important facts for investors to verify
- Whether the stated 12-month cash runway remains supportable given the $50.0 million of operating cash used in the first half and the timing of expected collaboration receipts.
- Clinical progress, funding requirements, and potential partnering or commercialization plans for LX4211 and telotristat etiprate.
- Actual final restructuring costs and realized savings after the workforce reduction.
- The assumptions and potential payment timing for the Symphony Icon liability and Texas job-creation obligations.
- Availability and terms of future financing, and the company’s ability to generate revenue beyond its historically limited collaboration and license sources.